Explore the coverage of KOVALTRY®
Cross-over study examining PK characteristics of KOVALTRY® and Advate® (N=18)

Explore the coverage of KOVALTRY®
Cross-over study examining PK characteristics of KOVALTRY® and Advate® (N=18)

Compared to Advate®, KOVALTRY® demonstrated, with statistical significance1:

48% AUC0-inf
16% longer half-life
30% lower clearance
Cross-over PK study results (geometric mean [%CV]) following single-dose administration (50 IU/kg) of KOVALTRY® and Advate® in 18 patients1
Chromogenic assay KOVALTRY® Advate® P value
AUC0-last
(IUh/dL)
2200
(23.9)
1550
(27.4)
<0.0001
AUC0-inf
(IUh/dL)
2440
(28.5)
1650
(31.0)
<0.0001
Cmax
(IU/dL)
151
(19.9)
153
(17.1)
0.32
t1/2
(h)
13.9
(25.1)
12.0
(23.3)
<0.0001
MRT
(h)
19.2
(27.4)
15.0
(27.9)
<0.0001
CL
(dL/h/kg)
0.021
(28.5)
0.030
(31.0)
<0.0001
Vss
(dL/kg)
0.39
(19.1)
0.46
(16.7)
<0.0001

AUC0-inf=area under the curve from time 0 to infinity.
AUC0-last=area under the curve from time 0 to the last data point.

CL=clearance.
Cmax=maximum concentration.
CV=coefficient of variation.

MRT=mean residence time.
t1/2=half-life.
Vss=apparent volume of distribution at steady state.

Download the KOVALTRY® Dosing and PK Brochure

Dosing and PK parameters of KOVALTRY® in a study of adults2:
The recommended dosing of KOVALTRY® for routine prophylaxis is 20–40 IU/kg 2x/week or 3x/week in adults. In a study of KOVALTRY®, PK parameters were measured after a single 50-IU/kg dose of KOVALTRY® in 21 previously treated patients ≥18 years old. The average area under the curve was 2103.4 IU•h/dL. The average maximum concentration was 133.1 IU/dL. The average half-life was 14.2 hours.

INDICATIONS

KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY® is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY®. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY® if symptoms occur and seek immediate emergency treatment.

KOVALTRY® may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation can occur following administration of KOVALTRY®. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY® is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥3%) were headache, pyrexia, and pruritus.

For additional important risk and use information, please see full Prescribing Information.

References: 1. Shah A, Solms A, Garmann D, et al. Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A [published online December 22, 2016]. Clin Pharmacokinet. doi:10.1007/s40262-016-0492-2. 2. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2016.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© 2017 Bayer.   All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.
Advate is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

Site Last Modified 12/2017